Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome

NCT07146880 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT07146880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07146880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 15, 2025
Completion date
September 21, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brugada syndrome (brs)